Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion

Description

Summary

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent, and in patients with peripheral T-cell lymphoma in combination with gemcitabine and oxaliplatin chemotherapy (GEMOX)

Official Title

TELLOMAK: T-cell Lymphoma Anti-KIR3DL2 Therapy. An Open Label, Multicohort, Multi-center Phase II Study Evaluating the Efficacy and Safety of IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T-cell Lymphoma

Keywords

Lymphoma, T-Cell Lymphoma, T-Cell, Cutaneous Lymphoma, T-Cell, Peripheral Mycosis Fungoides/Sezary Syndrome Mycoses Lymphoma Mycosis Fungoides Sezary Syndrome Gemcitabine Oxaliplatin IPH4102 Gemcitabine + Oxaliplatin

Eligibility

You can join if…

Open to people ages 18 years and up

  • Cohort 1:
  • Patients with relapsed/refractory Sezary Syndrome (SS) who have received at least 2 prior systemic therapies;
  • Prior treatment with mogamulizumab;
  • Patients should have blood stage B2 at screening based on central evaluation by flow cytometry;
  • Feasibility of obtaining at least 1 skin biopsy at screening.
  • Cohorts 2 and 3:
  • Patients with stage IB to IV Mycosis fongoïdes (MF);
  • KIR3DL2 expression (Cohort 2) or non-expression (Cohort 3) by immunohistochemistry performed centrally on at least one skin lesion;
  • Patients should have received at least 2 prior systemic therapies that may include biological agents;
  • Feasibility of obtaining at least 1 skin biopsy at screening;
  • Adequate baseline laboratory data: Hematology: CD4+ T-cells ≥ 200/μL.
  • Cohorts 4 and 5:
  • . Patients with relapsed/refractory Peripheral T Cell Lymphoma (PTCL) of the following subtypes:

PTCL-NOS, angioimmunoblastic T-cell lymphoma (AITL), or anaplastic large cell lymphoma (ALCL);

  1. . KIR3DL2 expression (Cohort 4) or non-expression (Cohort 5) by immunohistochemistry performed centrally on at least one involved lymph node;
  2. . Patients should have received at least 1 prior systemic therapy including an anthracycline-based chemotherapy. Patients who are not eligible for treatment with anthracycline based therapy are eligible for inclusion provided that they were treated with at least one prior systemic therapy;
  3. . Presence of at least 1 target lesion on PET/CT scan at screening;
  4. . Feasibility of obtaining 1 lymph node biopsy at screening.
  5. All cohorts:
  6. . Male or Female, at least 18 years of age;
  7. . ECOG performance status ≤2;
  8. . The patient must have a minimum wash-out period of 4 weeks between the last dose of prior systemic therapy (8 weeks for biological agents) and the first dose of IPH4102
  9. . Patients should have recovered from all adverse events related to prior therapy to ≤ grade 1;
  10. . Adequate baseline laboratory data
  11. . Women of childbearing potential (WOCBP) must have a negative serum beta-HCG pregnancy test result within seven days from start of treatment;
  12. . Women of childbearing potential and all men (and their female partners of childbearing potential) who are sexually active must agree to use adequate method of contraception at study entry, during treatment and for at least 9 months (270 days) following the last dose of study drug.

You CAN'T join if...

  • Cohorts 1 to 3:
  • Patients with evidence of large cell transformation (LCT) based on central histologic evaluation.
  • Cohorts 4 and 5:
  • Prior administration of gemcitabine and/or oxaliplatin;
  • Presence of grade 2 neurotoxicity or higher.
  • All Cohorts:
  • Known central nervous system (CNS) lymphoma;
  • Prior administration of lacutamab/IPH4102;
  • Concomitant administration of radiotherapy or systemic anti-cancer therapy including but not restricted to: chemotherapy, biological agents or immunotherapy;
  • Autologous stem cell transplantation less than 3 months prior to enrollment;
  • Prior allogenic transplantation;
  • Concomitant corticosteroid use, systemic or topical. However, stable dosage of topical steroids (maximum strength Class III according to World Health Organization (WHO) Classification of Topical Corticosteroids) and/or systemic steroids (≤10 mg prednisone equivalent/day) are allowed, if patient has been on a stable dose for at least 4 weeks prior to treatment start;
  • . Patients who have undergone major surgery ≤ 4 weeks prior to study entry;
  • . Patients with known NCI CTCAE grade 3 or higher active systemic or cutaneous viral, bacterial, or fungal infection;
  • . Patients who have active Hepatitis B or C virus infection;
  • . Patients who are known to be HIV-positive;
  • . Patients with a history of other malignancies during the past 5 years apart from the disease subject of this study. The following are exempt from the five-year limit: non-melanoma skin cancer, lymphomatoid papulosis, resected thyroid cancer, biopsy-proven cervical intraepithelial neoplasia or cervical carcinoma in situ;
  • . Pregnant or breastfeeding women;
  • . Patients with congestive heart failure, Class III or IV, by New York Heart Association (NYHA) criteria;
  • . Patients with known active autoimmune disease;
  • . Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment and/or comply with study protocol;
  • . Patients with dementia or altered mental status that would

Locations

  • Stanford Cancer Center in progress, not accepting new patients
    Stanford California 94305 United States
  • Washington University School of Medicine in progress, not accepting new patients
    Saint Louis Missouri 63130-4899 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Innate Pharma
ID
NCT03902184
Phase
Phase 2
Study Type
Interventional
Last Updated